Abstracts of papers on haemophilia from other journals

Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates. de Biasi R, Rocino A, Papa, ML, Salerno E, Mastrullo L, De Blasi D.
Rapid clearance of hepatitis C virus RNA in peripheral blood mononuclear cells of patients with clotting disorders and chronic hepatitis C treated with alpha-2b interferon is not a predictor for sustained response to treatment. Peerlinck K, Willerns M, Sheng L, Nevens F, Fevery J, Yap SH, Verrnylen J.
Factor VIII gene rearrangements in patients with severe haemophilia A. Goodeve AC, Preston FE, Peake IR.
Immune status of human immunodeficiency virus seropositive and seronegative hemophiliacs infused for 3.5 years with recombinant factor VIII. Mannucci PM, Brettler DB, Aledort LM, Lusher JM, Abildgaard CF, Schwartz RS, Hurst D and the Kogenate Study Group.
The role of platelet von Willebrand factor in platelet adhesion and thrombus formation: a study of 34 patients with various subtypes of type I von Willebrand disease. Fressinaud E, Federici AB, Castaman G, Rothschild C, Rodeghiero F, Baumgartner HR, Mannucci PM, Meyer D.
Two controlled trials of rifabutin prophylaxis against Mycobacteriurn aviurn complex infection in AIDS. Nightingale SD, Cameron DW, Gordin FM, Sullam PM, Cohn DL, Chaisson RE, Eron LJ, Sparti PD, Bihari B, Kaufman DL, Stern JJ, Pearce DD, Weinberg WG, LaMarca A, Siegal FP.
Three-year randomised study of high-purity or intermediate-purity factor VIII concentrates in symptom-free HIV-seropositive haemophiliacs: effects on immune status. Seremetis SV, Aledort LM, Bergman GE, Bona R, Bray G, Brettler D, Eyster ME, Kessler C, Lau T-S, Lusher J, Rickles F.